Close Menu

NEW YORK – Cardea Bio and Nanosens Innovations — the companies that teamed up to develop a CRISPR-Cas9-based biosensor diagnostic device using a graphene transistor called the CRISPR-Chip — announced today that they are merging.

Nanosens will become a subsidiary of Cardea, and the companies plan to sell CRISPR-Chip technology-based products under the Nanosens brand. Kiana Aran — an assistant professor and principal investigator at the Keck Graduate Institute of Applied Life Sciences, and cofounder of Nanosens — will join Cardea as chief science officer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A bipartisan group of senators has introduced a bill seeking increased funding for certain fields, including synthetic biology, ScienceInsider reports. 

The Los Angeles Times reports that a case of the novel coronavirus making people ill in China has been reported in the US. 

Discover magazine writes that paleoproteomics is increasing being used in archaeology, paleoanthropology, and paleontology, including a recent study of a 6,000-year-old ring. 

In Nucleic Acids Research this week: mutagenic effects of ultraviolet "A" light, post-transcription effects of synonymous mutations, and more.